Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Depreciation & Amortization (CF): 2010-2024

Historic Depreciation & Amortization (CF) for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $2.6 million.

  • China Pharma Holdings' Depreciation & Amortization (CF) fell 48.91% to $356,034 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 49.25%. This contributed to the annual value of $2.6 million for FY2024, which is 4.92% down from last year.
  • Latest data reveals that China Pharma Holdings reported Depreciation & Amortization (CF) of $2.6 million as of FY2024, which was down 4.92% from $2.8 million recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' Depreciation & Amortization (CF) ranged from a high of $3.1 million in FY2021 and a low of $2.6 million during FY2024.
  • Over the past 3 years, China Pharma Holdings' median Depreciation & Amortization (CF) value was $2.7 million (recorded in 2022), while the average stood at $2.7 million.
  • In the last 5 years, China Pharma Holdings' Depreciation & Amortization (CF) rose by 15.24% in 2021 and then dropped by 12.54% in 2022.
  • China Pharma Holdings' Depreciation & Amortization (CF) (Yearly) stood at $2.7 million in 2020, then increased by 15.24% to $3.1 million in 2021, then fell by 12.54% to $2.7 million in 2022, then rose by 1.97% to $2.8 million in 2023, then decreased by 4.92% to $2.6 million in 2024.